FDA Clearance Tracker · K261280
BioSieve Multi-Drug Urine Test Panel;BioSieve Multi-Drug Urine Home Test Panel
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 22, 2026
Substantially Equivalent
Time to decision
35 days
Received Apr 17, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K261280
- Device name
- BioSieve Multi-Drug Urine Test Panel;BioSieve Multi-Drug Urine Home Test Panel
- Applicant location
- Hangzhou, CN
- Received
- Apr 17, 2026
- Decided
- May 22, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Test, Amphetamine, Over The Counter (NFT)
- Device class
- Class II
- Regulation
- 21 CFR 862.3100
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NFT. The earliest in FDA's data is K170049, decided May 2, 2017.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K261280
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Vivachek Biotech (Hangzhou) Co., Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260687 · Decided Oct 9, 2026 · 220 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
K252554 · Decided Sep 12, 2025 · 30 days after receipt
Device type: Test, Amphetamine, Over The Counter (NFT) · Laboratory Medicine & Pathology
K241869 · Decided Oct 4, 2024 · 99 days after receipt
Device type: Test, Opiates, Over The Counter (NGL) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.